| Literature DB >> 29291157 |
Lavin Salih1, Staffan Tevell1,2, Emeli Månsson1,3, Åsa Nilsdotter-Augustinsson4, Bengt Hellmark1, Bo Söderquist1.
Abstract
The objective of the present study was to investigate the antibiotic susceptibility including mupirocin among Staphylococcus. epidermidis isolated from prosthetic joint infections (PJIs) (n=183) and nasal isolates (n=75) from patients intended to undergo prosthetic joint replacements. Susceptibility to mupirocin (used for eradication of nasal carriership of Staphylococcus aureus) was investigated by gradient test, and susceptibility to various other antimicrobial agents was investigated by disc diffusion test. All isolates, except three from PJIs and one from the nares, were fully susceptible to mupirocin. Multi-drug resistance (≥3 antibiotic classes) was found in 154/183 (84.2%) of the PJI isolates but only in 2/75 (2.7%) of the nares isolates, indicating that S. epidermidis causing PJIs do not originate from the nares.Entities:
Keywords: Antibiotic susceptibility testing; Mupirocin; Prosthetic joint infections; Staphylococcus epidermidis
Year: 2018 PMID: 29291157 PMCID: PMC5744189 DOI: 10.7150/jbji.22459
Source DB: PubMed Journal: J Bone Jt Infect ISSN: 2206-3552
Figure 1Distribution of minimum inhibitory concentrations (MICs) of mupirocin among S. epidermidis isolates obtained from prosthetic joint infections (a) and from nares (b). The breakpoints for nasal decolonization of S. aureus according to NordicAST (http://www.nordicast.org) is S ≤1 mg/L and R >256 mg/L, respectively.
Antibiotic susceptibility testing of S. epidermidis isolates obtained from prosthetic joint infections (PJIs) and from nares of patients intended for elective arthroplastic surgery. Multi-drug resistance (MDR) was defined as resistance against ≥3 antibiotic classes.
| PJIs (n=183)Resistant (%) | Nares (n=75)Resistant (%) | |
|---|---|---|
| Cefoxitin | 137 (74.9%) | 5 (6.7%) |
| Fusidic acid | 81 (44.3%) | 8 (10.7%) |
| Clindamycin | 105 (57.4%) | 2 (2.7%) |
| Erythromycin | 115 (62.8%) | 14 (18.7%) |
| Gentamicin | 130 (71.0%) | 2 (2.7%) |
| Rifampicin | 52 (28.4%) | 0 (0%) |
| Sulfamethoxazole/ | 134 (73.2%) | 7 (9.3%) |
| Norfloxacin | 148 (80.9%) | 3 (4.0%) |
| Mupirocin | 3 (1.6%) | 1 (1.3%) |
| MDR | 154 (84.2%) | 2 (2.7%) |